Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR), Waters (WAT) and Regeneron (REGN)
TD Cowen Maintains Waters(WAT.US) With Hold Rating, Maintains Target Price $363
Waters Corp Price Target Raised to $300.00/Share From $275.00 by Barclays
Jefferies Adjusts Price Target on Waters to $355 From $320
Waters Analyst Ratings
Leerink Partners Upgrades Waters(WAT.US) to Buy Rating, Raises Target Price to $375
Barclays Maintains Waters(WAT.US) With Sell Rating, Raises Target Price to $300
Waters (WAT) Gets a Sell From Barclays
TD Cowen Maintains Waters(WAT.US) With Hold Rating, Raises Target Price to $363
Waters Corporation: Hold Rating Maintained Amid Valuation Concerns and Cautious Outlook
Deutsche Bank Adjusts Waters Price Target to $310 From $330
Leerink Adjusts Price Target on Waters to $325 From $330
TD Cowen Adjusts Price Target on Waters to $325 From $358, Maintains Hold Rating
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Waters Analyst Ratings
Evercore ISI Adjusts Price Target on Waters to $300 From $320, Maintains In-Line Rating
Waters Analyst Ratings
Barclays Adjusts Price Target on Waters to $275 From $295
Deutsche Bank Adjusts Waters Price Target to $330 From $304
Waters Corporation: Hold Rating Affirmed Amidst Mixed Q1 Performance and Cautious Outlook
No Data